Clinigence Holdings (NUTX) AI Stock Analysis

• Market Cap: $506.35M
• Dividend Yield: N/A
• Average Volume (3M): 312.92K
• Price to Earnings (P/E): 7.9
• Beta (1Y): 2.37
• Revenue Growth: 141.25%
• EPS Growth: N/A
• Country: US
• Employees: 800
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 5,555,116
• 10 Day Avg. Volume: 232,277
• 30 Day Avg. Volume: 312,916
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 0.85
• Enterprise Value/Gross Profit: 1.73
• Enterprise Value/Ebitda: 2.47
• 1Y Price Target: $262.50
• Price Target Upside: 195.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 74 Outperform
• Price Target: $96.00 ▲(8.00% Upside)

Nutex Health shows strong financial growth and operational improvements, particularly highlighted by the recent earnings call. The company's robust financial performance and attractive valuation are balanced by technical indicators suggesting short-term challenges. Overall, the stock presents a promising long-term opportunity with some near-term risks.

Positive Factors

Expansion Plans

The company remains on track with its network expansion strategy, with three new micro-hospitals slated to open in Texas and a broader pipeline of seven De Novo facilities with targeted openings in the coming years.

Financial Performance

NUTX's growing free cash flow from operations, which increased significantly, may support acceleration of these expansion plans.

Revenue Growth

NUTX delivered a second consecutive quarter of significantly better-than-expected revenue, driven primarily by continued success in securing favorable reimbursement outcomes on underpaid claims through the No Surprises Act’s IDR process.

Negative Factors

Business Model Challenges

Shares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.

Market Position

Despite significant revenue growth, the stock faces challenges due to its early-stage development and the need to prove its business model in the competitive healthcare sector.

Clinigence Holdings Business Overview & Revenue Model

Company Description

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

How the Company Makes Money

Clinigence Holdings generates revenue through a combination of software licensing, subscription fees, and service contracts. Its primary revenue streams include fees from healthcare organizations, such as hospitals and clinics, for access to its data analytics and population health management platforms. Additionally, the company may enter into strategic partnerships with other healthcare entities to expand its service offerings and reach. Clinigence's solutions enable healthcare providers to optimize their operations, reduce costs, and improve patient outcomes, which in turn drives demand for its products and services. The company's growth is supported by the increasing shift towards value-based care models and the need for data-driven decision-making in the healthcare industry.

Clinigence Holdings Financial Statement Overview

Summary

Clinigence Holdings demonstrates strong revenue growth and profitability improvements with efficient operational cash flow management. However, increased leverage on the balance sheet could pose future risks.

Income Statement

Clinigence Holdings shows strong revenue growth with a significant increase in total revenue on a TTM basis compared to previous periods. The gross profit margin has improved, indicating efficient cost management. Net profit margin is healthy, reflecting profitability. However, historical volatility in EBIT and EBITDA margins suggests potential instability.

Balance Sheet

The balance sheet reflects moderate financial leverage with a debt-to-equity ratio that has increased, potentially raising risk. However, the return on equity is robust, signaling effective use of equity. Equity ratio is reasonable, indicating a stable asset base but with room for improvement in reducing liabilities.

Cash Flow

Operating cash flow has improved significantly, supporting a positive free cash flow trajectory. The operating cash flow to net income ratio suggests strong operational efficiency. However, historical fluctuations in free cash flow growth underscore potential variability in cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	479.95M	247.65M	219.29M	331.53M	273.42M
Gross Profit	196.26M	34.77M	13.45M	179.28M	271.60M
EBITDA	148.65M	-14.58M	-393.96M	183.45M	-5.12M
Net Income	52.18M	-45.79M	-432.74M	132.59M	105.97M
Balance Sheet
Total Assets	655.32M	398.25M	431.75M	394.65M	308.55M
Cash, Cash Equivalents and Short-Term Investments	43.58M	22.00M	34.26M	36.12M	25.51M
Total Debt	340.30M	275.76M	267.20M	178.55M	150.12M
Total Liabilities	453.43M	319.14M	311.42M	203.07M	161.19M
Stockholders Equity	146.34M	61.45M	95.86M	114.65M	85.81M
Cash Flow
Free Cash Flow	20.85M	-8.24M	35.97M	136.51M	20.07M
Operating Cash Flow	23.15M	1.26M	50.61M	173.43M	81.26M
Investing Cash Flow	-2.67M	-11.24M	-4.34M	-36.98M	-61.19M
Financing Cash Flow	1.09M	-2.27M	-48.13M	-125.85M	-2.56M

Clinigence Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 88.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Neutral. The current price of 88.89 is below the 20-day moving average (MA) of 100.60, below the 50-day MA of 119.42, and above the 200-day MA of 75.93, indicating a neutral trend. The MACD of -9.58 indicates Positive momentum. The RSI at 39.60 is Neutral, neither overbought nor oversold. The STOCH value of 32.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NUTX.

Clinigence Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	74 Outperform	$506.35M	7.86	51.65%	―	141.25%	―
HSTM	69 Neutral	$785.72M	38.69	5.81%	0.46%	3.50%	13.99%
TXG	65 Neutral	$1.66B	―	-22.03%	―	-0.13%	42.17%
Sector *	60 Neutral	HK$17.54B	4.97	-4.95%	3.61%	9.71%	-38.85%
EVH	58 Neutral	$1.12B	―	-10.99%	―	10.24%	2.63%
HCAT	58 Neutral	$265.88M	―	-19.80%	―	4.88%	37.87%
DH	53 Neutral	$567.79M	―	-86.36%	―	-3.04%	-152.59%

Clinigence Holdings Corporate Events

Clinigence Holdings Stockholders Approve Key Decisions

At the annual meeting of stockholders of Nutex Health Inc. held on July 14, 2025, several key decisions were made. All seven director nominees were elected for a one-year term, the compensation of executive officers was approved, an amendment to the 2023 Equity Incentive Plan was passed, and Grant Thornton LLP was ratified as the independent accounting firm for 2025.

The most recent analyst rating on (NUTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.

Nutex Health COO Joshua DeTillio Resigns

On July 8, 2025, Joshua DeTillio, the Chief Operating Officer of Nutex Health, Inc., announced his resignation effective August 8, 2025, to take on a CEO role at another company. His departure is amicable, with no disputes or disagreements involved, and the company’s Board of Directors is actively searching for his replacement.

The most recent analyst rating on (NUTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.